Cipla Limited (CIPLA) share price and analysis
CIPLA last traded at ₹1,388.00 (-0.47%) on the NSE. Market cap ₹1,12,135 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 5.1/10 (Average)
- Valuation: 5.7/10
- Profitability: 4.6/10
- Growth: 1.3/10
- Financial health: 7.3/10
- Price trend: 6.4/10
Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Long bias. Conditions favour buying dips over shorting.
Strengths of CIPLA
- Debt / equity (0.02): Virtually debt-free, with a strong balance sheet.
- Long-term trend (+1.8% vs 200-DMA): Just above its 200-day average. Still an uptrend, but not by much.
- Net profit margin (10.4%): Healthy profit margins.
- Current ratio (3.59): Plenty of short-term assets to cover short-term bills.
- 50-DMA vs 200-DMA (+0.1% gap): 50-day average is just above the 200-day. Momentum is turning up.
- Analyst target (₹1,507 (+8.6%)): 36 analysts' average target implies +8.6%, moderate upside.
- Momentum (RSI 14) (RSI 54): Mildly positive momentum.
- Volatility (1Y) (20% annualised): Low volatility. A relatively steady stock.
Weaknesses of CIPLA
- Profit growth (YoY) (-35.0%): Profits are falling sharply.
- Return on equity (8.3%): Below-average return on equity. Capital isn't working hard.
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
- Revenue growth (YoY) (-1.1%): Sales are shrinking slightly.
- 6-month performance vs Nifty 50 (-3.1% vs +7.4%): Lagging the Nifty 50.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 38.7 | In line with peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 22.3 | Profits expected to grow | below today's P/E (38.7) and near 41 |
| Price / book | 3.17 | Normal | 2–6 |
| EPS (TTM) | ₹35.84 | Profitable | above ₹0 |
| Return on equity | 8.3% | Weak | 15%+ (below 10% is weak) |
| Debt / equity | 0.02 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 10.4% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 13.0% | Average | 20%+ strong, below 10% thin |
| Revenue growth | -1.1% | Shrinking | 10%+ a year (below 3% is weak) |
| Profit growth | -35.0% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.93% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 3.59 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹1,539.70 | 10% below · mid-range | price in the top 40% of its 52-week range |
| 52W low | ₹1,165.70 | Price is 19% above it | |
| 50-DMA | ₹1,365.74 | Price 1.6% above | price above it = short-term uptrend |
| 200-DMA | ₹1,363.98 | Price 1.8% above | price above it = long-term uptrend |
| 1Y return | -8.2% | Lagged the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.10 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 31.1% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 45.0% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹1,507.31 | 8.6% upside · 36 analysts | 8%+ upside |
Questions about CIPLA
What is the share price of Cipla Limited (CIPLA) today?
CIPLA last traded at ₹1,388.00 (-0.47% on the day) on the NSE. Its 52-week range is ₹1,165.70 to ₹1,539.70. Prices are delayed and come from Yahoo Finance.
Is CIPLA a good stock for the long term?
StockLens rates CIPLA 5.1 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: low debt, uptrend, high margins. Concerns: falling profits, weak ROE, cash burn.
Is CIPLA share overvalued?
CIPLA trades at a P/E of 38.7 against a Pharma & Healthcare median of 41.1, which StockLens rates as "In line with peers". Its price-to-book ratio is 3.17.
Is CIPLA good for short-term trading?
The trade bias for the next few weeks is "Long bias": Conditions favour buying dips over shorting. The price is 1.8% above its 200-day average and 14-day RSI is 54.
Which stocks are similar to CIPLA?
Similar Pharma & Healthcare stocks of comparable size include Dr. Reddy's Laboratories, Zydus Lifesciences, Aurobindo Pharma, Apollo Hospitals, Max Healthcare. You can compare up to 4 of them side by side on StockLens.
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Stocks similar to CIPLA
- Dr. Reddy's Laboratories share price
- Zydus Lifesciences share price
- Aurobindo Pharma share price
- Apollo Hospitals share price
- Max Healthcare share price
- Laurus Labs share price
Compare CIPLA with DRREDDY, ZYDUSLIFE, AUROPHARMA
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.